Literature DB >> 26015275

Recent Advances in Traditional Chinese Medicine for Kidney Disease.

Yifei Zhong1, Madhav C Menon2, Yueyi Deng3, Yiping Chen3, John Cijiang He4.   

Abstract

Because current treatment options for chronic kidney disease (CKD) are limited, many patients seek out alternative therapies such as traditional Chinese medicine. However, there is a lack of evidence from large clinical trials to support the use of traditional medicines in patients with CKD. Many active components of traditional medicine formulas are undetermined and their toxicities are unknown. Therefore, there is a need for research to identify active compounds from traditional medicines and understand the mechanisms of action of these compounds, as well as their potential toxicity, and subsequently perform well-designed, randomized, controlled, clinical trials to study the efficacy and safety of their use in patients with CKD. Significant progress has been made in this field within the last several years. Many active compounds have been identified by applying sophisticated techniques such as mass spectrometry, and more mechanistic studies of these compounds have been performed using both in vitro and in vivo models. In addition, several well-designed, large, randomized, clinical trials have recently been published. We summarize these recent advances in the field of traditional medicines as they apply to CKD. In addition, current barriers for further research are also discussed. Due to the ongoing research in this field, we believe that stronger evidence to support the use of traditional medicines for CKD will emerge in the near future.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease (CKD); alternative medicine; animal models; anti-fibrotic; anti-inflammatory; anti-oxidant; clinical trials; glomerular disease; herbal medicine; immunomodulation; inflammation; renal disease; review; traditional Chinese medicine (TCM)

Mesh:

Substances:

Year:  2015        PMID: 26015275     DOI: 10.1053/j.ajkd.2015.04.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  37 in total

1.  A great honor and a huge challenge for China: You-you TU getting the Nobel Prize in Physiology or Medicine.

Authors:  Da Yuan; Xue Yang; Jun-Chao Guo
Journal:  J Zhejiang Univ Sci B       Date:  2016-05       Impact factor: 3.066

2.  Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis.

Authors:  Ming Wang; Dan-Qian Chen; Lin Chen; Gang Cao; Hui Zhao; Dan Liu; Nosratola D Vaziri; Yan Guo; Ying-Yong Zhao
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

Review 3.  Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.

Authors:  Jinghong Zhao; Zhihong Liu
Journal:  Pediatr Nephrol       Date:  2019-03-23       Impact factor: 3.714

4.  Chinese herbal medicines and chronic kidney disease: a positive outcome in a large patient study in Taiwan.

Authors:  Glenda C Gobe; Kunyu Shen
Journal:  Kidney Int       Date:  2015-12       Impact factor: 10.612

5.  Yi-Qi-Jian-Pi-Xiao-Yu-Xie-Zhuo Formula Improves Muscle Atrophy via Modulating the IGF-1/PI3K/Akt Signaling Pathway in 5/6 Nephrectomized Rats.

Authors:  Hong Xia; Bingbing Zhang; Dan Yang; Chengyue Zhu; Jiudan Zhang; Hongbo Chen; Hongzhen Ma; Shouci Hu; Chao Xu; Chengqian Shi; Keda Lu; Peipei Zhang
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

6.  A Chinese herbal formula, Jian-Pi-Yi-Shen decoction, improves muscle atrophy via regulating mitochondrial quality control process in 5/6 nephrectomised rats.

Authors:  Dongtao Wang; Jianping Chen; Xinhui Liu; Ping Zheng; Gaofeng Song; Tiegang Yi; Shunmin Li
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

7.  iTRAQ-Based Proteomics of Chronic Renal Failure Rats after FuShengong Decoction Treatment Reveals Haptoglobin and Alpha-1-Antitrypsin as Potential Biomarkers.

Authors:  Yu Yang; Junmeng Wei; Xuekuan Huang; Mingjun Wu; Zhenbing Lv; Pan Tong; Rui Chang
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-27       Impact factor: 2.629

8.  Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.

Authors:  Ping Li; Yi-Zhi Chen; Hong-Li Lin; Zhao-Hui Ni; Yong-Li Zhan; Rong Wang; Hong-Tao Yang; Jing-Ai Fang; Nian-Song Wang; Wen-Ge Li; Xue-Feng Sun; Xiang-Mei Chen
Journal:  Trials       Date:  2017-04-11       Impact factor: 2.279

Review 9.  Effects of Traditional Chinese Medication-Based Bioactive Compounds on Cellular and Molecular Mechanisms of Oxidative Stress.

Authors:  Bo Liang; Yong-Chun Zhu; Jia Lu; Ning Gu
Journal:  Oxid Med Cell Longev       Date:  2021-05-14       Impact factor: 6.543

10.  Total Flavones of Abelmoschus manihot Ameliorates Podocyte Pyroptosis and Injury in High Glucose Conditions by Targeting METTL3-Dependent m6A Modification-Mediated NLRP3-Inflammasome Activation and PTEN/PI3K/Akt Signaling.

Authors:  Bu-Hui Liu; Yue Tu; Guang-Xia Ni; Jin Yan; Liang Yue; Zi-Lin Li; Jing-Jing Wu; Yu-Ting Cao; Zi-Yue Wan; Wei Sun; Yi-Gang Wan
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.